ATS 2024 Final Program

Click on the session title to view the speakers

270

TUESDAY • MAY 21

P277 Real-world Safety and Efficacy of Riociguat in Adults With Pulmonary Arterial Hypertension: 6-month Data From the RiOciguAt UseRs (ROAR) Registry P278 Stratification of Risk of Pulmonary Hypertension Using Non-invasive Measures in Patients With Schistosomiasis-related Liver Disease in Ethiopia and Zambia P279 Increased Body Mass Index Is Associated With Reduced All-cause Mortality in Sarcoidosis-associated Pulmonary Hypertension P280 Pulmonary Hypertension Is Not Associated With Mortality After Thrombolysis in Acute Stroke. Analysis of National Inpatient Sample P281 The Definition of Pulmonary Hypertension Varies Widely Across Empiric Research Studies P282 Causal Association Between Platelet Counts and Pulmonary Arterial Hypertension: A Two-sample Mendelian Randomization Study P283 Advanced Pulmonary Hypertension Portends Worse Survival in Polycythemia Vera P284 Real-world Transition and Persistence to Oral Hypertension on Noncardiac Surgical Outcomes: A Systematic Review and Meta-analysis P286 Choice of Antidiabetic Therapy Is Associated With Survival in Patients With Pulmonary Hypertension and Diabetes P287 The Role of Pulmonary Hypertension in Patients Undergoing Atrial Fibrillation Ablation: National Inpatient Sample (NIS) P288 Case Series: Marked Attenuation of Methamphetamine-associated Pulmonary Arterial Hypertension With Methamphetamine Cessation and Pharmacologic Therapy P289 Impact of Group 1 Pulmonary Arterial Hypertension in Sepsis Hospitalizations P290 SGLT2 Inhibitors and Pulmonary Arterial Hypertension: A Retrospective Study P291 Predictors of Methamphetamine Use in the Midwest/Western United States: Xpose Treprostinil Therapy From Parenteral Prostacyclins in Patients With Pulmonary Arterial Hypertension P285 The Influence of Pre-existing Pulmonary

P292 Clinical Characteristics and Treatment Outcomes in Pulmonary Langerhans Cell Histiocytosis Associated Pulmonary Arterial Hypertension: A Retrospective Case Series P293 Clinical Characteristics and Treatment Outcomes in Hereditary Hemorrhagic Telangiectasia Associated Pulmonary Arterial Hypertension: A Retrospective Case Series P294 Characteristics of Methamphetamine-associated Pulmonary Arterial Hypertension at a Single Center P295 Diet Quality in Patients With Pulmonary Arterial Hypertension P296 Selexipag in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (PAH-CTD): Real-world Evidence From EXPOSURE

BASIC • CLINICAL • TRANSLATIONAL THEMATIC POSTER SESSION

C63 PEDIATRIC IMMUNOLOGY,

ONCOLOGY, PHYSIOLOGY, AND CELL BIOLOGY

9:15 a.m. - 4:15 p.m.

San Diego Convention Center Area A (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session Discussion: 11:30-12:30 Discussionwith facilitators, authors, andattendees 12:30-1:15 Authorswill beby their posters for individual discussionwithattendees P1 Complement Component C3 Modulates Surfactant in the Lung P2 Oscillometry Phenotypes in Children With Down Syndrome P3 Infant Pulmonary Function Testing Duration Differs by Anesthesia Type P4 Spectral and Intra-breath Oscillometry in Adolescents Living with Obesity P5 Functional Redundancy in Reparative T Cell Subsets Is Associated With Improved Respiratory Viral Infection Outcome P6 Anti-thymocyte Globulin for Maintenance Immunosuppression After Lung Transplantation Complicated by Acute Renal Failure

ATS 2024 Conference Program • San Diego, CA